Search Results for: Majority of Oncology Clinical Trials
Articles
Fierce Competition Amongst Checkpoint Inhibitor Developers Ahead March 16, 2018
Over the next ten years, PD-(L)1 inhibitors will continue to dominate the checkpoint modulators market, says leading data and analytics companyGlobalData.
DNA THERAPEUTICS - DNAbilize-ING Antisense March 15, 2018
Peter Nielsen, MBA, explains how his company’s candidates are differentiated from those in development at other companies by the type of modification to the antisense molecule and the method by which it is conveyed to its target cell.
Fierce Competition Amongst Checkpoint Inhibitor Developers Ahead February 28, 2018
Over the next ten years, PD-(L)1 inhibitors will continue to dominate the checkpoint modulators market, says leading data and analytics...Rexahn Pharmaceuticals Announces Collaboration With Zhejiang Haichang Biotechnology February 13, 2018
Rexahn Pharmaceuticals, Inc. recently announced it has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology Co., Ltd....GSK Exercises Option Over Adaptimmune’s SPEAR T-Cell Therapy Program September 7, 2017
Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, recently announced that GlaxoSmithKline plc has exercised its option...Galena Biopharma Enters Merger Agreement With SELLAS Life Sciences August 14, 2017
Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd recently announced they have entered into an all stock definitive merger...Immunocore Identifies Second Novel ImmTAC in GSK Collaboration May 15, 2017
Immunocore Limited recently announced it has identified a lead compound in its second discovery program with GSK. This novel ImmTAC...ASSAY VALIDATION - Biomarker Assay Validations – A Time for Change? May 1, 2017
John L. Allinson, FIBMS, believes despite the increased use of biomarkers, it appears that many researchers are still continuing to use the FDA guidance document for validation even though it only critically addresses the validation of assays to support PK evaluation, and also has a limited scope described within the document in terms of studies where it should be used.
SPECIAL FEATURE - Formulation Development & Manufacturing - CDMOs Offer Speed, Advanced Technologies, & the Ability to Handle More Potent APIs April 4, 2017
Contributor Cindy H. Dubin speaks with some of the industry’s leading CDMOs to highlight their capabilities in the areas of speed, quality, technology, and handling of complex APIs.
AAV VECTOR MANUFACTURING - Challenges & Opportunities in the Manufacturing of AAV Vectors Used in the Delivery of Gene Therapy Treatments February 28, 2017
Daniel C. Smith, PhD, indicates there remains a clear need for improved process productivities, and the need to develop manufacturing processes that can be applied to a wide number of AAV-based viral vector therapeutic candidates.
NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025 November 7, 2016
INTRODUCTION GlobalData estimates that the value of the Non-Small Cell Lung Cancer (NSCLC) market in the 8 major markets (8MM)...Aegerion Pharmaceuticals & QLT Agree to Strategic Merger June 20, 2016
Aegerion Pharmaceuticals, Inc. and QLT Inc. recently announced they have entered into a definitive merger agreement under which Aegerion will...DRUG DEVELOPMENT EXECUTIVE - Crown Bioscience: Enhancing the Drug Development Process May 31, 2016
Jean Pierre Wery, President of Crown Bioscience, discusses the requirement for more accurate research models in oncology research, focusing on PDX models that have the ability to more adequately represent the conditions and mechanisms of immunotherapy in human patients.
ANTIGEN-SCREENING SYSTEM - Perfecting the Promise of T Cell Therapies for Infectious Disease & Cancer May 31, 2016
THE EVOLUTION OF IMMUNOTHERAPIES The human body is armed with an efficient and elegant immune system that fights pathogens and...IMMUNOTHERAPY RESEARCH - The Shift Toward Combination Therapies March 30, 2016
Jean Pierre Wery, PhD, indicates immunotherapy in combination with traditional treatments has the potential for becoming a more effective alternative to the current standard of care. These types of combination therapies are currently under investigation and appear to have synergistic effects compared to the use of one therapy alone.
NANOSCALE COMPLEXES - A Novel Nanotechnology-Based Platform to Optimize Combination Cancer Therapies: Rational Development & Improved Delivery Using CombiPlex® January 7, 2016
Barry D. Liboiron, PhD; Arthur C. Louie, MD; et al describe how CombiPlex addresses the challenges facing the traditional development path of many contemporary drug combinations and provide clinical proof-of-principle evidence that this approach can yield marked improvements in efficacy and patient outcomes.
SPECIAL FEATURE - Outsourcing Formulation & Manufacturing Development: Using Data & Unique Approaches to Solve Solubility Issues, Target Profiles & Customize Products March 31, 2015
Contributor Cindy H. Dubin finds that CMOs are embracing development projects in an effort to establish longer-lasting partnerships with their pharma and biotech clients. These contract developers are deploying innovative techniques aimed at improving solubility and fast-tracking products to market.
SPECIAL FEATURE - Injectable Drug Delivery: Safer, Simpler, Smarter Devices September 4, 2014
Contributor Cindy H. Dubin speaks with some of the leading companies operating in the injectables arena, and discovers this ever-evolving sector is witnessing some very specific and eye-opening trends that are affecting the market’s growth.
FIXED-DOSE COMBINATIONS - Fixed-Dose Combination Products - What’s in the Clinic? (Part 3 – Pipeline) May 7, 2014
Tugrul T. Kararli, PhD, MBA; Kurt Sedo; and Josef Bossart, PhD, believe the pharmaceutical industry has been paying increasing attention to the potential of Fixed-Dose Combination products, and conclude this series of three articles, examining the past, present, and future of these products with the intent of understanding their whats and whys.
MARKET BRIEF - Latin America Next-Generation Biosimilars Market: Opportunities & Future Growth March 4, 2014
Lucila Rocca, Healthcare Industry Analyst, Frost & Sullivan, indicates the Latin American Biosimilars market will grow at a significant rate in the next 5 years, and the importance of establishing rigorous regulation will stimulate this market growth.
